Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 7/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009916 | 0.91 | NAMPT (0.43) | NAMPTGAAFFAR4L3MBTL1SCN5A | |
| SCHEMBL2010372 | 0.79 | GPBAR1 (0.39) | GPBAR1FFAR4RORCSCN5ASCN9A | |
| SCHEMBL2011222 | 0.77 | GPBAR1 (0.40) | GPBAR1FFAR4SCN5ASCN9A | |
| SCHEMBL29130060 | 0.75 | TSHR (0.51) | GAARORCL3MBTL1GRM2SCN5A | |
| SCHEMBL27780155 | 0.73 | GPBAR1 (0.41) | GPBAR1FFAR4RORCSCN5ASCN9A | |
| SCHEMBL15336756 | 0.72 | TSHR (0.58) | GAATSHR | |
| SCHEMBL10165058 | 0.72 | ALDH1A1 (0.51) | GRM2 | |
| SCHEMBL8217999 | 0.70 | SCN10A (0.39) | RORCL3MBTL1 | |
| SCHEMBL30625715 | 0.70 | CHRM4 (0.48) | NAMPTL3MBTL1GRM2 | |
| SCHEMBL10264167 | 0.70 | CHRM4 (0.48) | NAMPTL3MBTL1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | RIPK1 4535/4885GPBAR1 65/4885NAMPT 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.